Cytek Biosciences (CTKB) closed out FY 2025 with Q4 revenue of US$62.1 million and a basic EPS loss of US$0.34, alongside a trailing twelve month revenue base of US$201.5 million and a basic EPS loss of US$0.52. Over recent periods, the company has seen quarterly revenue move from US$57.5 million in Q4 2024 to US$62.1 million in Q4 2025, while basic EPS shifted from a profit of US$0.07 in Q4 2024 to a loss of US$0.34 in Q4 2025. This sets up a story that puts margin pressure and the path back to profitability firmly in focus for investors.

See our full analysis for Cytek Biosciences.

With the headline numbers on the table, the next step is to set these results against the prevailing market and community narratives to see which stories around Cytek Biosciences hold up and which are challenged by the latest margin trends.

Losses widen to US$66.5 million over the year

• On a trailing twelve month basis to Q4 2025, Cytek Biosciences reported net income excluding extra items of a US$66.5 million loss, compared with a US$6.0 million loss a year earlier. Q4 2025 alone accounted for US$44.1 million of that annual loss.
• Bears focus on this widening loss profile, pointing out that losses have grown at an annualized rate of 67.6% over five years and that forecasts in the provided data still show no path to profitability over the next three years.
  • This trailing twelve month loss of US$66.5 million alongside a basic EPS loss of US$0.52 contrasts with the small loss of US$6.0 million and basic EPS loss of US$0.05 in the prior trailing period, which critics see as evidence of sustained margin pressure.
  • The step from a Q4 2024 net income of US$9.6 million to a Q4 2025 net loss of US$44.1 million is used by the cautious view as a concrete example of how earnings volatility can work against shareholders when a business is not yet consistently profitable.

Skeptics argue this swing from a small trailing loss to a US$66.5 million loss could be a warning sign that the road back to profitability may be longer than many holders expect. They unpack that argument in more detail in the 🐻 Cytek Biosciences Bear Case.

Revenue base near US$201 million but growth expectations are modest

• Trailing twelve month revenue sits at US$201.5 million as of Q4 2025, and the data supplied indicates revenue is forecast to grow at 6.6% per year compared with a wider US market forecast of 11.4% per year.
• The consensus style narrative highlights recurring services and reagents as a potential support for future revenue. However, the 6.6% forecast growth rate, below the 11.4% market rate, gives investors a clear tension between a growing installed base and more modest headline growth expectations.
  • Quarterly revenue has moved from US$51.5 million in Q3 2024 to US$62.1 million in Q4 2025 based on the figures provided, which fits with the idea of a meaningful revenue base but does not on its own point to rapid expansion.
  • Analysts in the balanced view also point to tools like Cytek Cloud and AI driven bioinformatics as helping instrument and reagent usage. The current 6.6% revenue growth forecast in the data suggests that any boost from these areas is, at least for now, expected to translate into steady rather than rapid top line progress.

Lower 3.2x P/S offers a valuation cushion if the bullish case plays out

• The company trades on a P/S of 3.2x, which sits below both the US Life Sciences industry average of 3.4x and a peer average of 4.5x, while the current share price is US$4.92 versus an analyst consensus target of US$6.00.
• Supporters of the bullish narrative argue that expanding high margin recurring revenue from reagents and software, plus a growing installed base, could make that lower P/S an attractive entry point if operating performance aligns with their expectations.
  • The bullish view in the supplied data assumes revenue growth of 8.6% per year and a move in profit margins from a loss making position today to industry like levels. This is a different stance from the 6.6% growth rate and continued losses highlighted in the risk summary and gives you a sense of the spread in expectations.
  • Against that backdrop, the gap between the US$4.92 share price and the US$6.00 consensus target shows how much of that potential improvement the analyst community, on average, is currently building into their models, even though the same data set still indicates the company is expected to remain unprofitable over the next three years.

If you want to see how bullish investors connect this 3.2x P/S and US$201.5 million revenue base to a more optimistic long term story, you can walk through their full case in the 🐂 Cytek Biosciences Bull Case.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Cytek Biosciences on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

After considering both the bullish and cautious perspectives, the key question is how you view the trade off between growth, losses, and valuation for yourself. If you want to stress test your view against the downside, take a close look at the 1 important warning sign.

See What Else Is Out There

Cytek Biosciences combines a US$201.5 million revenue base with widening losses and modest growth expectations, which leaves investors carrying meaningful earnings and execution risk.

If that trade off feels uncomfortable, you can quickly compare this profile against companies screened for 72 resilient stocks with low risk scores to see if a steadier option suits you better.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.